Thomas Gad
CIK 1753224 · CHIEF BUSINESS OFFICER · last filed 2025-09-18
Thomas Gad is a CHIEF BUSINESS OFFICER who has filed 103 SEC Form 4 insider transactions across 1 company since 2018. Across all open-market trades the lifetime net is −$47.5M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
103
-$47.45M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Y-mAbs Therapeutics, Inc. (YMAB) Delisted | CHIEF BUSINESS OFFICER | 365,721 | $8.61 | $3.15M | -$47.45M | 102 | 2025-06-05 |
Recent Filings
103 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-09-18 | — | Mixed | −433,402 | -$3.21M | |
| 2025-06-05 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Exer (M) | +103,000 | $206.0K | EDGAR |
| 2025-03-11 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Sell (S) | −10,810 | -$56.5K | EDGAR |
| 2025-01-22 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +32,000 | $0 | EDGAR |
| 2024-09-20 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Exer (M) | +22,831 | $100.0K | EDGAR |
| 2024-09-17 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Sell (S) | −95,000 | -$1.26M | EDGAR |
| 2024-06-11 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Sell (S) | −70,000 | -$841.0K | EDGAR |
| 2024-05-23 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Sell (S) | −32,351 | -$395.6K | EDGAR |
| 2024-03-07 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Sell (S) | −3,900 | -$64.1K | EDGAR |
| 2024-01-22 | Y-mAbs Therapeutics, Inc. (YMAB) Delisted | Grant (A) | +22,100 | $0 | EDGAR |